Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1915 - Is standard adjuvant chemotherapy effective in patients with Epstein-Barr virus associated gastric cancer?

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Jong Gwang Kim

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

J.G. Kim1, Y. Chae2, J.H. Baek3, B.W. Kang1

Author affiliations

  • 1 Oncology, Kyungpook National University Hospital, 700-721 - Daegu/KR
  • 2 Oncology, Kyungpook National University Medical Center, 702-911 - Daegu/KR
  • 3 Oncology, Ulsan University Hospital, 44033 - Ulsan/KR
More

Resources

Abstract 1915

Background

Based on a comprehensive molecular characterization of gastric cancer, Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) can be classified as one of the four subtypes of gastric cancer (GC). Several studies have shown significantly better prognosis of EBVaGC compared with EBV-negative GC (EBVnGC). However, no published study has yet investigated the clinical significance of standard adjuvant chemotherapy in patients with resected EBVaGC. Accordingly, the present study analyzed the prognostic differences between EBVaGC and EBVnGC, and their survival impacts on standard adjuvant chemotherapy.

Methods

This study retrospectively reviewed 773 patients with gastric cancer who underwent surgical resection at Kyungpook National University Chilgok Hospital, between January 2011 and December 2017. The patients were enrolled according to the following criteria: 1) pathologically diagnosed with primary gastric adenocarcinoma, 2) the presence of test using EBV-encoded RNA in situ hybridization, 3) stage II/III according to the seventh edition of the UICC/AJCC for the stomach, and 4) postoperative adjuvant chemotherapy.

Results

Among 276 eligible patients, 59 (21.4%) and 217 patients (78.6%) were determined as EBVaGC and EBVnGC, respectively. One hundred twenty-nine (46.7%) patients were classified as stage II and 147 (53.3%) were as stage III. As for adjuvant chemotherapy, 87 patients (31.5%) received capecitabine and oxaliplatin (XELOX), while 189 (68.5%) received S-1, respectively. With a median follow-up duration of 21.3 months (2.4-89.0), the estimated 3-year disease-free survival (DFS) and overall survival (OS) rates were 74.8% and 83.0%, respectively. In a univariate analysis and multivariate analysis using a Cox proportional hazard model, EBV-positivity was not significantly associated with disease-free survival (p = 0.630) for all patients and XELOX or S-1 group.

Conclusions

In conclusion, EBV-positivity was not found to be associated with prognosis in patients with curatively respective gastric cancer who received standard adjuvant chemotherapy. Accordingly, the standard adjuvant chemotherapy can be used for patients with EBVaGC.

Clinical trial identification

Legal entity responsible for the study

Jong Gwang Kim.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.